Intratumoral injection of recombinant adenoviral type 5 ( Ad5 ) vectors that carry prodrug -activating enzymes like DT -diaphorase ( DTD ) could be used to selectively target tumor cells for chemotherapy. To demonstrate the feasibility of this approach, Ad5 vectors were constructed, which express human DTD minigenes for both wild -type and mutant ( C -to -T change in nucleotide 609 in DTD cDNA ) DTD under the control of the cytomegalovirus ( CMV ) promoter. HT29 human colon carcinoma cells express wild -type DTD, whereas BE human colon carcinoma cells express mutant DTD, have low to undetectable DTD activity, and are 4 -to 6 -fold more resistant to mitomycin C ( MMC ) than HT29 cells. A test of the ability of Ad5 to infect these cells ( using a -galactosidase CMVdriven minigene ) indicated that 90 -100% of BE cells were infected at a multiplicity of infection ( MOI ) of 100, whereas only 15 -40% of HT29 cells were infected at this MOI. Infection of BE cells in vitro with recombinant Ad5 carrying a minigene for wild -type DTD at MOIs of 3 -100 resulted in a progressive increase in DTD activity and a maximal 8 -fold increase in sensitivity to MMC as measured by a colony -forming assay. HT29 cells were sensitized 2 -to 3 -fold following treatment with Ad5.DTD at an MOI of 100. These results indicate that adenovirus -mediated gene transfer and expression of wild -type DTD can sensitize resistant tumor cells to MMC and that this therapeutic strategy may exert a significant bystander effect.
I dentification of drugs that are selectively toxic to malignant cells has been a long -term goal of chemotherapy as a mode of cancer treatment. 1 -3 One approach is to utilize nontoxic prodrugs that are selectively activated in solid tumors as a consequence of microenvironmental differences between tumors and normal tissue (e.g., oxygen level differences ). 4 Recently, gene therapy approaches have been have been developed in which prodrugs are selectively activated following intratumor injection of viral vectors able to express drug -activating enzymes. 5, 6 In many cases, these ''suicide genes'' code for viral or bacterial enzymes that activate novel prodrugs. Examples include the herpes simplex gene coding for a thymidine kinase, which is 1000 times more efficient in phosphorylating the antiviral nucleoside analogue ganciclovir, and the Escherichia coli gene coding for cytosine deaminase, which converts 5 -fluorocytosine to 5 -fluorouracil, a widely used chemotherapeutic agent clinically. Both these agents have been shown to exert significant bystander effects, 5, 6 but their efficiency depends to a large extent on the rate of target tumor cell growth. Prodrug systems in which the active form of the drug is an alkylating agent have been suggested as a means to target both cycling and quiescent tumor cells. 7 For example, bioreduction of the prodrug CB1954 by an E. coli nitroreductase to form an alkylating agent has recently given promising results in experimental tumor models. 8 In the present study, we examined whether the widely studied and clinically used drug mitomycin C (MMC ) can be used as a prodrug 9 in conjunction with human DTdiaphorase ( DTD ), which has the ability to activate MMC in cell -free systems but whose role in cells as a key activating enzyme is still controversial.
10 DTD [NAD(P )H:quinone oxidoreductase (NQO1); Enzyme Commission no. 1.6.99.2 ] is a homodimeric, cytosolic flavoenzyme that acts on its substrates by a concerted two -electron reduction process, avoiding an oxygen -sensitive free radical intermediate in producing the hydroquinone. 11 The hydroquinone of MMC undergoes chemical rearrangements, resulting in a bifunctional alkylating agent capable of crosslinking DNA. 12 Elevated DTD activities have been reported in tumor relative to normal tissue 13 and in tumor cell lines. 14 It has been suggested that this difference be exploited using compounds that are DTD substrates. 12 A high degree of heterogeneity in DTD enzymatic activities 15 and protein levels 16 has been observed both within and across normal and tumor tissue types. This is due to factors such as DTD gene expression levels 17 and a high -frequency C -to -T base change at nucleotide 609 of the DTD coding region. This base transition causes a proline-to -serine change in amino acid 187, resulting in impaired DTD catalytic activity and protein instability. 15, 18 Individuals homozygous for this mutation exhibit little or no DTD activity and heterozygotes have approximately half the DTD activity observed in wild -type cells. 18, 19 Homozygous mutants have a much reduced sensitivity to MMC under aerobic exposure conditions in vitro. 10, 15 To reduce the problem of heterogeneity and to enhance DTD activity in tumor cells, recombinant adenoviral vectors were constructed, which express DTD minigenes for both wild -type and mutant ( C -to -T base change ) DTD under the control of the cytomegalovirus (CMV ) promoter. These vectors were used to overexpress recombinant DTD in human colon cancer cells that are homozygous for either wild -type ( HT-29, MMC -sensitive ) or mutant DTD ( BE, MMC -resistant ). Assessments of DTD protein levels and enzymatic activities in relation to MMC sensitivity, as determined by in vitro colonyforming assays, demonstrated that the adenoviral vector expressing DTD /MMC combination represents a novel and effective prodrug activation strategy for cancer treatment.
Materials and methods

Chemicals and reagents
All reagents used for the DTD enzymatic assay were purchased from Sigma ( St. Louis, MO ). Materials used for polymerase chain reaction, including AmpliTaq polymerase, were obtained from Roche Molecular Systems (Branchburg, NJ ). DTD monoclonal antibodies B771 and A180 were supplied by Dr. David Ross (University of Colorado Health Sciences Center, Denver, CO ). Antihuman integrin V ( MAB1960) was purchased from Chemicon ( Temecula, CA ). MMC (catalog no. M4287 ), X -gal, potassium ferricyanide, and potassium ferrocyanide, used for histochemical detection of -galactosidase ( -gal ), were also purchased from Sigma.
Cell culture
293T human embryonic kidney cells were obtained from Microbix Biosystems ( Toronto, Ontario, Canada ) for the production of E1 -defective recombinant adenoviral type 5 ( Ad5 ). HeLa human cervical carcinoma cells, used to test for wild -type recombinant virus, were purchased from American Type Culture Collection ( Manassas, VA ). BE and HT29 human colon carcinoma cells were chosen on the basis of previous work that showed a 6 -fold difference in MMC sensitivity due to low or absent DTD activation in BE cells, 15 and that both cells can be infected by Ad5 ( unpublished data ). BE and HT29 human cells were obtained from Dr. T Mulcahy ( Wisconsin Clinical Cancer Centre, Madison, WI ). All cell lines were maintained as monolayer cultures in growth medium consisting of -minimal essential medium supplemented with 10% fetal bovine serum (Cansera; Rexdale, Ontario, Canada ), growth medium, and maintained in a humidified atmosphere containing 5% CO 2 at 378C in 175 cm 2 polystyrene tissue culture flasks (Nunc, Life Technologies, Burlington, Ontario, Canada ).
Generation of replication -defective adenoviral vectors
A modified Ad5 shuttle vector, pÁE1sp1CMV, containing a CMV promotor and a bovine growth hormone poly A signal inserted in the polylinker of pÁE1Sp1 ( Microbix Biosystems ) was used as a eukaryotic expression vector. 20 HindIII -XbaI fragments containing the human DTD cDNA with a C or T nucleotide at position 609 were isolated from pRc /CMV.DTD 609C and pRc /CMV.DTD 609T , respectively. 21 The fragments were inserted into the corresponding restriction sites of pÁE1sp1Rc /CMV to generate pÁE1sp1.DTD 609C and pÁE1sp1.DTD
609T
. All plasmid constructs were sequence-verified (Core Molecular Biology Facility, York University, Toronto, Canada ).
Ad5.DTD vectors were produced according to a modification of the method developed by McGrory et al.
22
293T cells were cotransfected through the CaPO 4 coprecipitation method 23 . Testing for wildtype Ad5 contamination using HeLa cells was negative. 24 Polymerase chain reaction reactions on DNA isolated from viral particles using DTD gene -specific primers or Ad5 fiber protein gene -specific primers confirmed the presence of both DTD (bp 261 -721 of DTD cDNA ) and fiber protein ( bp 5861 -6151 of the Ad5 genome from JM17 ) coding regions in the Ad5.DTD viruses, indicating successful recombination between vectors.
Infection of BE and HT29 cells with Ad5. -gal BE and HT29 (1Â10 5 per well ) were seeded in six -well tissue culture dishes ( Nunc ) in 3 mL of growth medium and incubated overnight in a humidified atmosphere containing 5% CO 2 at 378C. Growth medium was gently aspirated from each well and overlaid with 0.5 mL of serum -free -MEM containing recombinant Ad5.CMV. -gal under the control of the CMV promoter 20 at multiplicities of infection (MOI) of 3, 10, 30, 60, or 100 pfu /cell. After 30 minutes at 378C, 3 mL of growth medium was added to each well. Histochemical detection of -gal -positive cells was performed 48 hours later. 26 Infection efficiency of Ad5. -gal was assessed by determining the mean fraction of -gal -positive cells in five random 4.3 mm 2 fields at Â80 magnification. Positive cells were scored independent of variations in color intensity.
Western blot analysis of HT29 and BE cells or BE cells infected with Ad5.DTD
BE or HT29 cells (50 cells/ mm
2 ) were seeded in 10 -cmdiameter tissue culture dishes (Nunc ) containing 10 mL of growth medium and incubated overnight in a humidified atmosphere containing 5% CO 2 at 378C. Cells were
Cancer Gene Therapy DT-diaphorase expression via an Ad5 vector V Misra et al overlayed with 1 mL of serum -free -MEM containing an MOI of 10 or 100 of Ad5.DTD 609C or Ad5.DTD 609T for 30 minutes. Ten milliliters of growth medium was added to each dish and, after 48 hours, cells were harvested by scraping. Total cell protein extracts were prepared, protein concentrations determined, and Western blot and densitometry analyses carried out as described previously, 19 with the exception that blots were probed for integrin V expression ( using a 1:1000 dilution of antihuman integrin V ) as a loading control and protease inhibitors were not used.
DTD assay
DTD enzyme activity was measured using the substrate, 2,6 -dichlorophenolindophenol (DCPIP ), as previously described. 21 DTD enzyme activity in Ad5.DTD -infected BE cells BE cells were infected at an MOI of 10 or 100 with Ad5.DTD 609C and DTD enzyme activity determined 24, 48, and 72 hours postinfection. In one experiment, BE cells infected with Ad5.DTD 609C at an MOI of 100 were trypsinized at the 48-hour time point, the cells were reseeded at the 48-hour time point, and DTD activity was determined 48 hours later (96 hours after infection ).
Clonogenic survival of cells exposed to MMC
BE or HT29 cells in 10 -cm dishes were infected with Ad5.DTD 609C or Ad5.DTD 609T at various MOIs for 48 hours before MMC exposure. MMC stocks were prepared by reconstitution with PBS at 1 mg /mL and stored for up to 1 month at 48C in the dark. Stock concentrations were verified by measuring absorbance at 363 nm ("= 21,840 cm
. In experiments requiring MMC treatment, medium (with or without virus ) was replaced with 10 mL of growth medium containing MMC at the desired concentrations and cells were incubated with drug for 1 hour in a humidified atmosphere containing 5% CO 2 at 378C. After MMC exposure, medium containing drug was decanted and residual drug was removed by washing cells with 5 mL of PBS.
Cells were harvested by trypsinization and pelleted by centrifugation at 250Âg for 5 minutes at 48C. Pellets were resuspended in 10 mL of growth medium and cell density was assessed by 0.2% trypan blue (Life Technologies ) exclusion. Cell dilutions were prepared at 10 4 , 10 3 , and 10 2 cells /mL, and 1 mL of each dilution was plated in 60Â15 mm dishes ( Nunc ) in duplicate ( for drug -treated cells) or in triplicate ( untreated controls ) and incubated as before. Colonies were counted 12-14 days later after staining with 0.5% methylene blue ( Sigma) dissolved in equal parts ethanol to water. Plating efficiency was assessed by dividing the number of observed colonies by the total number of cells plated. The mean ± SEM (n =5) plating efficiencies of uninfected HT29 and BE control cells were 0.84± 0.09 and 0.69 ± 0.12, respectively. Fold sensitivities of BE cells infected at various MOIs of Ad5.DTD 609C to MMC were determined by comparing the ratio of dose ( g /mL ) required to achieve 1log of cell kill relative to the initial plating efficiency to that of BE cells infected with Ad5.DTD 609T .
Statistics
One -way analysis of variance (ANOVA ) was used to compare mean DTD activities of uninfected and Ad5.DTD 609T -infected HT29 cells. This procedure involves calculation of ( a ) each activity variance from the overall mean; ( b) variance within group ( uninfected or Ad5.DTD 609T -infected cells ) means; and ( c) variance between group means. The Student's t test was used to compare the mean survival of BE cells infected with Ad5.DTD 609C at an MOI of 100 for 48 hours and uninfected controls. ANOVA of regression was used to compare the MMC sensitivities of HT29 cells infected with Ad5.DTD 609C and uninfected controls.
Results
Infection of HT29 and BE cells with Ad5. -gal or Ad5.DTD
A single-base transition corresponding to nucleotide 609 of DTD cDNA ( C -to -T ) has been shown to result in impaired DTD activity and decreased protein stability. 18, 19 HT29 cells ( homozygous for the wild -type DTD allele ) displayed mean ± SEM (n = 5) DTD activity of 1060 ± 215 nmol / min / mg protein, whereas BE cells (homozygous for the variant DTD allele ) contained very low to undetectable DTD activity ( less than 20 nmol /min /mg protein ). Consistent with the fact that the variant allele promotes decreased DTD protein stability, 19 HT29 cells display Western blot reactivity whereas BE cells express very low to undetectable levels of DTD protein. However, low levels of the 609T isoform can be detected by increasing antibody incubation time and /or protein concentration ( data not shown ).
Preliminary studies of Ad5. -gal infection of HT29 and BE cells had demonstrated that BE cells were transduced more efficiently than HT-29 cells ( unpublished data ). The present work verified this observation (Fig 1) . At an MOI of 100, only 15% of HT29 cells stained positive for Ad5. -gal, whereas BE cells were infected at >90% efficiency.
The levels of recombinant DTD protein expressed in human BE cells following Ad5 infection were assessed by Western blot analysis ( Figs 2 and 3 ) . Monolayers of BE cells were infected with Ad5.DTD 609C and Western blot reactivity was determined 48 hours postinfection (Fig 2A ) . As shown in Figure 2B , densitometric analysis indicated that BE cells infected at an MOI of 100 contained three to four times greater DTD 609C protein levels than cells infected at an MOI of 10 when normalized to integrin V loading controls. Similar levels of 609T isoform expression were observed following Ad5.DTD 609T infection of BE cells at 10 and 100 pfu/cell ( Fig 3 ) . The lower molecular weight band ( 0.5-1 kDa smaller than wild -type DTD ) observed in Figure 3A may be a result of proteolytic processing or chemical degradation of the 609T isoform 19 and was included in the densitometric analysis.
Ad5.DTD infection of human cells and enzyme activity
To assess whether exogenous expression of the 609T DTD isoform modulates the enzymatic activity of the wild -type DTD allele, such as through a dominant negative effect, 27 HT29 monolayer cultures were infected with Ad5.DTD
609T
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at an MOI of 100. DTD activity was determined 48 hours later and compared to uninfected controls. No significant differences were observed in DTD enzymatic activities in Ad.DTD 609T -infected HT29 cells and uninfected controls ( P >0.1, one -way ANOVA, data not shown ).
The ability of Ad5.DTD 609C to express functional exogenous DTD was tested by measuring DTD activities in BE cells at different times postinfection. In particular, this kinetic study was used to assess whether sufficient exogenous DTD activity can be achieved in human cells for in vitro MMC sensitization. 10 6 BE cells were infected with Ad5.DTD 609C at an MOI of 10 or 100 and DTD activities were assessed at various time points postinfection. As shown in Figure 4 , BE cells infected at 100 MOI with Ad5.DTD 609C displayed a linear increase in DTD enzyme activity up to 72 hours postinfection. Activity peaked at around 2400 nmol of DCPIP reduced /min / mg protein. However, beyond 72 hours, a significant proportion of cells began to lift ( monolayers reached confluency at 48 hours postinfection ) and DTD activity declined. In one experiment, BE cells infected with Ad5.DTD 609C at an MOI of 100 were trypsinized and reseeded at a 1:2 dilution and activity was determined 48 hours later (96 hours postinfection ). Enzyme activity at this point remained high ( around 2000 nmol of DCPIP reduced / min /mg protein ), indicating that exogenous DTD continued to be expressed after trypsinization and plating ( data not shown ).
However, a slower rate of increase in DTD activity was observed in cells infected at an MOI of 10 and activity plateaued after 24 hours at around 250 nmol of DCPIP reduced /min /mg protein. At 48 hours postinfection, cells infected with an MOI of 100 displayed DTD activities of around 1320 ± 70 nmol of DCPIP reduced /min /mg protein, which is similar to that observed in uninfected HT29 cells. These results demonstrate that infection of BE cells with Ad5.DTD 609C at an MOI of 100 results in a linear increase in DTD activity over time and within the range of DTD activity in HT29 cells.
Clonogenic survival of Ad5.DTD -infected cells exposed to MMC
HT29 and BE cells have been previously used to demonstrate the association of the variant DTD allele with MMC resistance. 15, 28 In accordance with previous acute 1 -hour MMC exposure studies comparing drug sensitivity of human cells containing wild -type and variant DTD alleles, 29 BE cells displayed a 4-to 6 -fold resistance to MMC compared to HT29 cells at the 10% survival level when assessed for colony -forming ability 12 -14 days after exposure (Fig 5A ) . To examine whether exogenous expression of wild -type DTD could sensitize resistant cells to MMC, BE cells were infected with Ad5.DTD 609C at an As shown in Figure 5B , BE cells infected with Ad5.DTD 609C at an MOI of 100 were 8-fold more sensitive to MMC compared to cells infected with Ad5.DTD 609T , as determined by the ratio of MMC doses required to achieve 1log cell kill from the initial PE. However, untreated BE cells infected with Ad5.DTD 609C had a reduced plating efficiency compared to uninfected controls ( mean PE ± SEM, n =3, 0.45 ± 0.11 vs 0.69 ±0.12, respectively, P < .05, Student's t test ) indicating toxicity due to expression of exogenous wild -type DTD. This toxicity is not due to the vector itself because untreated BE cells infected with Ad5.DTD 609T at an MOI of 100 had a plating efficiency of 0.81± 0.14 ( Fig 5B ) , which is in the range of uninfected control cells. BE cells infected with Ad5.DTD 609T exhibited no major increases in MMC sensitivity, consistent with previous observations of impaired catalytic activity and protein instability of the DTD 609T isoform. 18, 19 As shown in Figure 5C , exogenous expression of DTD was confirmed in cells infected with Ad5.DTD 609C by assessing DTD activities in cells that were infected in parallel with the MMC sensitivity studies described above.
HT29 cells infected with Ad5.DTD 609C were 2 -fold more sensitive to MMC than uninfected controls (Fig 5B ) , although no significant increase in DTD activity was seen compared to uninfected cells (Fig 5C ) . There was no effect of the virus on the plating efficiency of control cells, which was in the range of uninfected cells. ANOVA of regression indicated that HT29 cells infected with Ad5.DTD 609C at an MOI of 100 were significantly more sensitive to MMC than uninfected controls (P < .01). These results show that Ad5.DTD 609C can be used to sensitize BE cells to MMC. At an MOI of 100, DTD activities are similar to HT29 cells after 48 hours. Ad5.DTD 609C infection also sensitizes HT29 cells to MMC despite the low infection efficiency compared to BE cells.
To assess the effect that different levels of exogenous wild -type DTD expression would have on MMC sensitivity, BE cells were infected with Ad5.DTD 609C at MOIs ranging from 3 to 100 (Fig 6A ) . DTD activities 48 hours postinfection increased linearly with MOI ( Fig 6B ) . As before, BE cells infected with Ad5.DTD 609C at an MOI of 100 displayed reduced plating efficiency (mean PE ±SEM was 0.42 ± 0.06) compared to uninfected controls (mean plating efficiency 0.8± 0.1 ). Also, as shown in Figure 6A , drug sensitivity was dependent on MOI. Similar acute MMC toxicities were observed between BE cells infected with Ad5.DTD 609C at an MOI of 60 and uninfected HT29 cells. However, BE cells displayed less than 50% of the DTD activity (mean ± SEM was 495± 13 nmol of DCPIP reduced /min / mg protein; Fig 6B ) of HT29 cells ( 1060 ± 215 nmol of DCPIP reduced /min /mg protein ) measured previously.
In these experiments, BE cells infected with Ad5.DTD
609C
at an MOI of 100 exhibited four to five times higher sensitivity to MMC relative to cells treated at an MOI of 60 in terms of the ratio of doses corresponding to 1log cell kill from initial PE. Because DTD activity determinations in HT29 cells can vary by as much as 2-fold from one experiment to another, it is possible that MOIs greater than Cancer Gene Therapy DT-diaphorase expression via an Ad5 vector V Misra et al 60 are required to achieve equivalent MMC toxicity in BE cells. These results show that transduction of BE cells with Ad5.DTD 609C at MOIs of 10 -100 pfu /cell provides for a continual increase in the sensitization to MMC.
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Discussion
Bioreductive enzyme -prodrug therapy involves the use of compounds that undergo metabolic reduction to cytotoxic metabolites. 4 One barrier to this approach is insufficient levels of activating enzymes in tumor tissue. 16 DTD is a bioreductive enzyme that can activate a variety of prodrugs, including quinone -based drugs, to DNA alkylating agents. DTD activity has been reported to be elevated in a range of tumor types 30 such as in human non -small cell lung cancer, 13, 14 breast, liver, 31 and colon tumors relative to surrounding normal tissue. It has been proposed that various prodrugs that are substrates for DTD could be useful for the treatment of tumors with high DTD activity. 32 However, not all tumors express high levels of DTD. Heterogeneity in DTD expression has been reported in the National Cancer Institute ( USA ) human tumor cell line panel, which includes cell lines derived from leukemic, lung, colon, and breast tumors. 30 This conclusion was based on both DTD mRNA expression levels and Western blot analysis. Heterogeneity was observed both within and across tumor cell types, but a correlation was observed between DTD expression and MMC sensitivity in this panel. DTD enzymatic activity has also been shown to be comparable in breast and lung tumor samples relative to corresponding normal tissue. 31, 32 Further complicating the heterogeneous nature of DTD expression across tissue types is the role of a single -base change, a C -to -T transition in nucleotide 609 of DTD cDNA, conferring a predicted proline -to -serine change in amino acid 187. This base change is frequent in the population 33 and has been associated with reduced catalytic activity, protein instability, and MMC resistance. 15, 18, 21 One way to address this problem is to introduce a bioreductive enzyme like DTD into tumor cells using gene transfer techniques. 34 Gene therapy strategies involving the delivery of activating enzymes to sensitize human tumors to prodrugs have been explored using nonmammalian enzymes, such as herpes simplex virus thymidine kinase 35 and E. coli cytosine deaminase 36 in combination with the nucleoside analogues ganciclovir and 5 -fluorocytosine, respectively. In the current study, human DTD coding sequences were delivered using a first generation replication -defective adenoviral vector to increase DTD activity and sensitize tumor cells to MMC.
BE cells express low to undetectable levels of DTD activity and protein 15, 21 and are good hosts for Ad5 infection ( Fig 1) . Infection of BE cells with Ad5.DTD 609C ( wt DTD ) or Ad5.DTD 609T (mt DTD ) produced DTD protein levels that increased with MOI (Figs 2 and 3 ) and DTD activities consistent with these protein levels ( and the known activities ) of wild -type and mutant DTD (Fig 4 ) . HT29 cells infected with wild -type DTD did not show a significant increase in DTD activity, probably due to the lower infection efficiency of these cells by Ad5 ( Fig 1 ) . Conversely, they did not show any loss of activity when Cancer Gene Therapy DT-diaphorase expression via an Ad5 vector V Misra et al infected with mutant DTD. The possibility that the mutant allele might have a dominant negative effect 27 on wild -type DTD activity has been eliminated by recent work showing that a 5 -fold excess of the mutant isoform over the wildtype form has no effect on DTD activity. 37 The linear increase in DTD activity with time following infection at an MOI of 100 (Fig 4 ) is consistent with previous work demonstrating that wild -type DTD protein has a half -life that is greater than 24 hours. 18 The leveling -off of DTD enzyme activities after 24 hours in BE cells infected with Ad5.DTD wild type at an MOI of 10 may reflect a balance between the rates of recombinant DTD production and degradation. In BE cells infected at an MOI of 100, the degradation pathway may be overwhelmed by the production pathway, resulting in a continuous increase in DTD. In MMC sensitization studies, BE cells were treated with MMC 48 hours postinfection with wild -type DTD at an MOI of 100. Of the two MOIs and various times postinfection of Ad5.DTD 609C tested, an MOI of 100 for 48 hours was chosen because it results in maximal DTD activity and optimal cell viability (Fig 4 ) . Untreated BE cells were 4 -to 6 -fold more resistant to MMC than HT29 cells ( Fig 5A ) . However, treatment with Ad5.DTD 609C at an MOI of 100 resulted in an 8 -fold increase in MMC sensitivity relative to BE cells infected with Ad5.DTD 609T at an MOI of 100 when assessed by clonogenic survival 12-14 days subsequent to a 1-hour exposure to MMC (Fig 5B ) . Increased sensitivity to MMC can be attributed to expression of exogenous wild -type DTD, and not to the Ad5 vector itself because transduction of BE cells with Ad5.DTD 609C resulted in only a 33% reduction in plating efficiency and treatment with Ad5.DTD 609T had no effect on BE cell survival. No evidence for resistant BE cells was seen down to 4-5logs of cell kill, suggesting that all cells were infected.
Interestingly, HT29 cells infected with Ad5.DTD 609C at 100 MOI were 2-fold more sensitive to MMC compared to uninfected controls ( Fig 5B ) despite exhibiting similar DTD activities (Fig 5C ) . Recent work, using cell lines expressing different levels of DTD, has shown that bioreductive activation of the quinone-containing compound RH1 has both a threshold and an apparent saturation level as a function of enzyme activity. 38 In addition, it has been shown that the subcellular location of a prodrug-activating enzyme is important for drug activation. 39 An interplay between both these factors may be important for understanding the present results. Because the -gal assay indicated 15-40% infection of Ad5.DTD 609C -infected HT29 cells at this MOI, the absence of a resistant cell subpopulation was surprising. Ad5.DTD 609C infection had no apparent effect on the cell plating efficiency. One possibility is the -gal assay underestimates the percent of cells infected. A second possibility is that MMC activation results in a bystander effect, though this has not been previously reported. The possibility of a MMC bystander effect is under study currently.
DTD activity increased linearly in BE cells as a function of Ad5.DTD 609C dose up to an MOI of 100 pfu / cell. ( Fig 6B ) . Also, sensitization of BE cells was shown to be dose -dependent because a series of Ad5.DTD 609C titrations ( Fig 6A ) at MOIs of 3, 10, 30, 60, or 100 resulted in 0.7 -, 1.0-, 1.1-, 3 -, or 8-fold increases in MMC sensitivity. It is important to point out that increased cell killing with increasing MOI may be a function of both increased DTD expression per cell as well as an increasing fraction of cells transfected (Fig 1) . Some caution must also be exercised in comparing HT29 and BE cell responses to MMC. Though differences in the MMC sensitivity appear to be mediated to a large degree by DTD levels, these cells are not isogenic and may express different levels of other activating or repair enzymes. 40 The present results support further studies in an in vivo model. However, the results of a recent independent study using a BE cell stably transfected with human DTD were disappointing because wild -type DTD expressing BE cells growing as a solid tumor in vivo were not sensitized to MMC relative to control BE cells. 40 However, the levels of DTD activity were so low in these tumors that the interpretation of the data was difficult. This reduction in DTD activity may reflect extinction or clonal variations in DTD expression with tumor growth. Clearly, the ability to express high levels of DTD in vivo will be crucial to the success of this therapeutic strategy. The use of DTD isoforms that are more catalytically efficient than wild -type human DTD, 41, 42 and the use of drugs that exhibit a substantial bystander effect 43 could also significantly improve the therapeutic potential of this strategy.
In summary, first generation recombinant Ad5 vectors have been constructed, which express both the wild -type and mutant isoforms of DTD. Treatment of MMC -resistant BE cells with the wild -type isoform increased MMC sensitivity 8 -fold, raising the possibility that gene therapy strategies, which sensitize tumors to drugs bioreductively activated by DTD, can be developed.
